Diphenylhydantoin-induced pure red cell aplasia.
The pathogenesis of diphenylhydantoin-induced pure red cell aplasia was investigated in the case of a 32-year-old man who developed pure red cell aplasia while he was under treatment with diphenylhydantoin. The patient's serum IgG purified from serum drawn at the time of diagnosis suppressed normal allogeneic marrow colony-forming (CFU-E) and burst-forming (BFU-E) and autologous blood BFU-E growth in vitro only in the presence of diphenylhydantoin. This IgG-diphenylhydantoin complex had no effect on CFU-GM growth in vitro. Normal IgG or patient's IgG purified from serum drawn after the remission of red cell aplasia had no effect on erythroid colony formation in vitro in the presence of diphenylhydantoin. The IgG-diphenylhydantoin complex exerted no direct cytotoxic effect on normal marrow erythroblasts, CFU-E, and BFU-E, nor did it interfere with the action of erythropoietin on marrow erythroblasts. These studies suggest that diphenylhydantoin-induced red cell aplasia is immunologically mediated through an IgG inhibitor, which requires the presence of the drug to suppress erythroid colony formation in vitro. This inhibitor seems to exert its effect on erythroid progenitors at or beyond the stage of differentiation of CFU-E, but not on erythroblasts.
D000328:Adult; D001488:Basilar Artery; D001854:Bone Marrow Cells; D004920:Erythropoiesis / Q000187:drug effects; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D002532:Intracranial Aneurysm / Q000188:drug therapy; D008297:Male; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced*
D007074:Immunoglobulin G; D010672:Phenytoin